EP Patent

EP2276756B9 — Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists

Assigned to Merck Sharp and Dohme LLC · Expires 2012-08-15 · 14y expired

What this patent protects

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

USPTO Abstract

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

Drugs covered by this patent

Patent Metadata

Patent number
EP2276756B9
Jurisdiction
EP
Classification
—
Expires
2012-08-15
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.